Stay informed with the latest litigation news. Explore now

Akebia Therapeutics competitive analysis

Latest publications and patents of Akebia Therapeutics New

Explore the latest publications and patents granted to Akebia Therapeutics, showcasing their recent innovations and technological advancements.

Last updated on: Sep 6, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Akebia Therapeutics

Feb 7, 2024Compositions And Methods For Treating AnemiaGranted And Under Opposition
May 11, 2022Prolyl Hydroxylase Inhibitors And Methods Of UseGranted And Under Opposition
Oct 27, 2021Compositions And Methods For Treating AnemiaOpposition Rejected

Explore patent oppositions filed by Akebia Therapeutics against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 11, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

Methods Of Increasing Endogenous Erythropoietin (Epo)FIBROGENFeb 10, 2020
Medicaments For Increasing Endogenous Erythropoietine (Epo)FIBROGENApr 3, 2019
Medicaments For Increasing Endogenous Erythropoietin (Epo)FIBROGENApr 3, 2019
Use Of Hif Alpha Stabilizers For Enhancing ErythropoiesisFIBROGENJul 6, 2015

Explore Akebia Therapeutics's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 11, 2025
Patent NumberGrant DateTitleTotal Oppositions
Feb 7, 2024Compositions And Methods For Treating Anemia1
May 11, 2022Prolyl Hydroxylase Inhibitors And Methods Of Use1
Oct 27, 2021Compositions And Methods For Treating Anemia1

Latest PTAB cases involving Akebia Therapeutics New

Discover the latest PTAB cases involving Akebia Therapeutics, highlighting their recent legal challenges and patent disputes.

Top competitors of Akebia Therapeutics

Top competitors of Akebia Therapeutics based on patent oppositions.